The Top 5 Analyst Questions From Integra LifeSciences’s Q1 Earnings Call
Integra LifeSciences reported a Q1 performance that exceeded expectations, driven by strong demand for tissue reconstruction products, improved supply, and operational initiatives. The company's revenue and adjusted EPS surpassed analyst estimates, leading to a positive market reaction. Analysts questioned the CEO transition, the status of their Compliance Master Plan, portfolio optimization, revenue guidance, and market share recapture efforts for product relaunches.
Paradigm Capital holds 4.01M shares of Integra LifeSciences (IART)
Paradigm Capital Management, Inc. has disclosed a 5.16% stake in Integra LifeSciences Holdings Corp (IART), holding 4,012,698 shares of Common Stock as of March 31, 2026. This ownership, reported via a Schedule 13G SEC filing, indicates a passive investment where Paradigm Capital exercises sole voting and dispositive power on behalf of its advisory clients. The filing highlights that these holdings exceed the 5% reporting threshold for passive institutional investors.
Integra LifeSciences (IART) director receives 17,700 RSU grant
Integra LifeSciences director Shaundra Clay was granted 17,700 restricted stock units (RSUs) on May 7, 2026, as part of the company's equity incentive plan. These RSUs, each representing one share of IART common stock, will vest fully on the one-year anniversary of the grant date. Clay has opted to defer the receipt of these shares until after her service on the Board ends.
Integra (IART) director receives 24,338-share stock awards
Integra Lifesciences Holdings Corp (IART) director Barbara B. Hill was granted 24,338 shares of common stock on May 7, 2026, as equity compensation. This included two awards of 17,700 shares and 6,638 shares, both at $0.00 per share. Following these transactions, Hill directly owns 151,191 shares, with an additional 36,350 shares held indirectly through a trust.
Renee Wonlai Lo awarded 17,700 RSUs at Integra LifeSciences (IART)
Integra LifeSciences director Renee Wonlai Lo was granted 17,700 Restricted Stock Units (RSUs) as equity compensation. These RSUs, which represent a contingent right to receive one share of IART common stock each, will vest in full on May 7, 2027, the one-year anniversary of the grant date. This award increases her reported RSU holdings to 17,700 units, aiming to align her interests with shareholder value.
Integra LifeSciences (IART) director Jeffrey Graves receives 17,700 RSU award
Integra LifeSciences Holdings Corp. director Jeffrey A. Graves was granted 17,700 Restricted Stock Units (RSUs) on May 7, 2026, under the company's 2003 Equity Incentive Plan. Each RSU represents a contingent right to one share of IART common stock, and the award vests in full on the one-year anniversary of the grant date. Following this transaction, Graves directly holds 17,700 RSUs.
Integra LifeSciences (IART) director awarded 17,700 deferred RSUs
Integra LifeSciences director Christian S. Schade was granted 17,700 restricted stock units (RSUs) on May 7, 2026, which will vest entirely one year from the grant date. Schade has elected to defer the receipt of these shares until after his service on the Board of Directors concludes. This award was part of the company's Fifth Amended and Restated 2003 Equity Incentive Plan, with a transaction price of $0.00, indicating a compensation grant rather than a purchase.
Integra LifeSciences to Present at the BofA Securities 2026 Health Care Conference
Integra LifeSciences Holdings Corporation announced that CFO Lea Knight will present at the BofA Securities 2026 Health Care Conference on May 12, 2026, at 4:20 pm PT. A live webcast of the presentation will be available on the company's investor relations website. The company is a global medical technology leader focusing on neurosurgery and tissue reconstruction.
Integra LifeSciences (NASDAQ: IART) expands equity plan and elects full board
Integra LifeSciences Holdings Corporation announced the results of its 2026 Annual Meeting, where stockholders approved an increase of 3,550,000 common shares for its equity incentive plan. All director nominees were elected with significant support, and PricewaterhouseCoopers LLP was ratified as the independent auditor. Additionally, stockholders provided advisory approval for the compensation of named executive officers.
IART CLASS ACTION ALERT: Hagens Berman Encourages Integra LifeSciences (IART) Investors with Substantial Losses to Contact Firm’s Attorneys, Securities Fraud Lawsuit Pending
Hagens Berman is encouraging Integra LifeSciences (IART) investors who suffered substantial losses to contact their attorneys regarding a securities fraud class action lawsuit. The lawsuit alleges that Integra made false and misleading statements about remediating FDA violations at its Boston Facility, leading to a global recall of products and a significant lowering of revenue and EPS guidance. Investors who purchased shares between March 11, 2019, and May 22, 2023, and experienced losses are urged to submit their information.
Integra LifeSciences to webcast May 12 BofA conference talk
Integra LifeSciences announced that CFO Lea Knight will present at the BofA Securities 2026 Health Care Conference on May 12, 2026, at 4:20 PM PT. A live webcast of the presentation will be available on the company's investor relations website. This presentation follows recent positive developments for Integra LifeSciences, including strong Q1 2026 results and leadership changes.
Integra LifeSciences Holdings Corporation (NASDAQ:IART) Q1 2026 Earnings Call Transcript
Integra LifeSciences Holdings Corporation reported strong Q1 2026 earnings, beating expectations with an EPS of $0.54. Stuart Essig has returned as President and CEO, emphasizing a focus on strengthening organizational culture, customer engagement, and commercial execution, alongside ongoing quality and transformation initiatives. The company maintained its full-year 2026 revenue guidance while updating adjusted EPS guidance to $2.40-$2.50, reflecting favorable tariff outcomes.
Integra: Q1 Earnings Snapshot
Integra LifeSciences Holdings Corp. (IART) reported a first-quarter loss of $4.6 million, or 6 cents per share. Despite the loss, adjusted earnings of 54 cents per share surpassed Wall Street expectations. The medical device maker also exceeded revenue forecasts, posting $391.9 million for the period, and provided a positive outlook for full-year earnings and revenue.
Integra LifeSciences Holdings Corporation (IART) Releases Q1 2026 Earnings: Revenue Up but EPS Miss
Integra LifeSciences Holdings Corporation (IART) reported Q1 2026 earnings with revenue up 2.4% year-over-year to $391.9 million, exceeding consensus estimates. However, the company missed EPS expectations, reporting -$0.06 per share, an 81.8% decline from the prior year. Operating profit also saw a significant decline, while insider trading showed net purchases and institutional investors had mixed activity.
Integra LifeSciences (IART) Beats Q1 Earnings and Revenue Estimates
Integra LifeSciences (IART) reported Q1 earnings of $0.54 per share, surpassing the Zacks Consensus Estimate of $0.41, and revenues of $391.92 million, also beating estimates by 2.74%. The company has consistently exceeded EPS estimates in the last four quarters. Despite outperforming expectations, Integra's shares have decreased by 14.3% year-to-date, contrasting with the S&P 500's gain, and currently hold a Zacks Rank #3 (Hold).
Integra LifeSciences Q1 EPS $0.54, lifts 2026 view | IART Stock News
Integra LifeSciences reported Q1 2026 revenue of $391.9 million, a 2.4% increase, and adjusted EPS of $0.54, up from $0.41 in the prior year. The company reaffirmed its full-year 2026 revenue guidance and raised its adjusted EPS outlook to $2.40-$2.50. This positive performance was driven by solid product demand and operational improvements, including double-digit growth in Integra Skin.
Integra LifeSciences Announces Leadership Transition
Integra LifeSciences has announced a leadership transition, with Stuart M. Essig appointed as the new President and Chief Executive Officer, effective May 1, 2026. Essig, who has been chairman of the board since 2012 and previously served as CEO, succeeds Mojdeh Poul. Additionally, Michael McBreen has been appointed Chief Commercial Officer in a newly created role to enhance commercial strategy and execution.
Stuart Essig returns as Integra LifeSciences (NASDAQ: IART) CEO
Integra LifeSciences announced that Stuart M. Essig has returned as President and CEO, while also retaining his role as Chairman of the Board, effective May 1, 2026. This leadership change follows Mojdeh Poul's departure and includes significant compensation for Essig and the appointment of Michael McBreen as the new Chief Commercial Officer. The company emphasizes continuity and a renewed focus on execution and customer strategy.
Integra LifeSciences (NASDAQ: IART) boosts 2026 adjusted EPS outlook
Integra LifeSciences reported first-quarter 2026 revenue of $391.9 million, a 2.4% year-over-year increase, and raised its full-year 2026 adjusted EPS guidance to $2.40–$2.50 from $2.30–$2.40, citing benefits from IEEPA tariffs. The company's profitability strengthened, with adjusted gross margin increasing to 64.1% and adjusted EBITDA reaching $76.2 million. While sales in Tissue Reconstruction grew, Specialty Surgery remained relatively flat, and the company maintains an elevated leverage ratio with $1.60 billion in net debt.
Integra LifeSciences (IART) to Release Earnings on Tuesday
Integra LifeSciences (NASDAQ:IART) is scheduled to release its Q1 2026 earnings before market open on Tuesday, May 5th. Analysts anticipate earnings of $0.42 per share and revenue of $381.8 million, aligning with the company's guidance of $0.370-$0.450 EPS for Q1. Despite beating the previous quarter's EPS, the company faces a "Reduce" consensus rating from analysts with a target price of $14.20, reflecting mixed signals due to a negative net margin and year-over-year revenue decline.
Integra LifeSciences Holdings Corporation (NASDAQ:IART) Receives Average Recommendation of "Reduce" from Analysts
Integra LifeSciences Holdings Corporation (NASDAQ:IART) has received an average "Reduce" recommendation from analysts, with a mean 12-month price target of $14.20. This comes despite the company beating Q4 EPS estimates, as revenue was down year-over-year and several firms have cut their price targets, including Citigroup to $9. Hedge funds and institutional investors hold a significant portion of the stock.
IART Price Today: Integra LifeSciences Holdings Stock Price, Quote & Chart | MEXC
This article provides current stock information for Integra LifeSciences Holdings (IART), including its live price, key market data, and recent performance metrics. It highlights that IART is trading at $10.69, having seen a +1.18% increase today, but a -35.96% change over the last 12 months, classified as a small-cap stock within the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector. The article also includes details on how to buy IART stock on MEXC and offers a comprehensive FAQ section addressing common investor queries regarding its financials and market position.
INTEGRA SHAREHOLDER ALERT: Kaskela Law Firm Announces Shareholder Investigation of ...
Kaskela Law Firm has initiated an investigation into Integra LifeSciences Holdings Corp. (NASDAQ: IART) concerning potential breaches of fiduciary duty claims on behalf of long-term shareholders. This investigation follows a securities fraud complaint alleging that Integra issued false and misleading statements regarding its compliance with Good Manufacturing Practices. The complaint states that investors learned the full truth about Integra's "systematic, serious, and recurring" violations and shipping holds in July 2022, leading to a 21% stock price decline.
Integra LifeSciences to Host First Quarter 2026 Financial Results Conference Call on May 5, 2026
Integra LifeSciences Holdings Corporation (NASDAQ: IART) announced it will release its first quarter 2026 financial results on Tuesday, May 5, 2026, before the market opens. Management will host a conference call at 8:30 a.m. ET, with a live webcast available on the Company’s investor relations website. Participants are encouraged to register in advance for dial-in details.
Integra LifeSciences posts Q1 results May 5 before market open
Integra LifeSciences (NASDAQ: IART) will release its first-quarter 2026 financial results on Tuesday, May 5, 2026, before market open. Management will host a conference call at 8:30 a.m. ET, with a live webcast available on the company's investor website. Historical data suggests that similar earnings call announcements have typically led to mild negative stock movements, with an average change of -2.36%.
Argus Research downgrades Integra LifeSciences Holdings (IART)
Argus Research has downgraded Integra LifeSciences Holdings (IART). The article is a stub and provides no further details on the reasons for the downgrade or any financial implications.
Integra LifeSciences (NASDAQ: IART) extends $150M receivables facility to 2029
Integra LifeSciences Holdings Corporation has extended its $150 million accounts receivable securitization facility until April 10, 2029. This extension, achieved through amendments to the Receivables Financing Agreement and Purchase and Sale Agreement, ensures the company maintains access to diversified funding for ongoing liquidity and working capital needs. The amendments also adjust certain representations, covenants, and concentration limits related to the receivables backing the facility.
Integra LifeSciences (NASDAQ:IART) Shares Gap Down After Analyst Downgrade
Integra LifeSciences (NASDAQ:IART) shares gapped down following a price target cut from Truist Financial. Several other analysts have also lowered their ratings or price targets for the company, contributing to a "Reduce" average rating and a consensus target price of $14.20. Despite slightly beating Q4 EPS and revenue expectations, the company reported a negative net margin and offered conservative FY2026 EPS guidance.
Integra LifeSciences Unveils New Real-World Evidence Highlighting PriMatrix® Utilization
Integra LifeSciences (Nasdaq: IART) is set to present new real-world data on its PriMatrix® Dermal Scaffold at three major medical conferences in April. The data, derived from 985 cases involving 117 surgeons, demonstrate PriMatrix's effectiveness across various complex wound types, including surgical, traumatic, chronic ulcers, and burn injuries. These findings reinforce the company's commitment to evidence-based solutions in wound reconstruction and care.
Integra LifeSciences Unveils New Real-World Evidence Highlighting PriMatrix Utilization
Integra LifeSciences will present new real-world data on its PriMatrix Dermal Scaffold at three major medical conferences in April, including analyses from nearly 1,000 cases across various wound types and a case series on burn injuries. The company emphasizes the product's role in complex reconstruction and limb salvage, adding to a growing body of evidence for its wound reconstruction portfolio. These presentations reinforce Integra's commitment to evidence-based solutions in advanced wound care.
Integra LifeSciences (NASDAQ: IART) posts 2025 loss and seeks approval of equity plan
Integra LifeSciences (NASDAQ: IART) is seeking stockholder approval for several proposals at its 2026 annual meeting, including the election of directors and an amendment to its equity incentive plan to increase available shares. The company reported a GAAP net loss of $516.5 million in 2025 despite a 1.5% increase in revenue to $1.64 billion, driven by significant investments in quality systems and infrastructure. The executive compensation program prioritizes pay-for-performance, with most executive compensation tied to company and individual performance goals, including annual organic revenue growth and, starting in 2026, adjusted EBITDA margin.
985 wound-care cases: Integra takes PriMatrix data to 3 conferences
Integra LifeSciences will present new real-world data for its PriMatrix dermal scaffold at three medical conferences in April 2026. The data, derived from 985 cases involving 117 surgeons and a 23-patient burn series, highlight the scaffold's use across various complex wound types, including diabetic foot ulcers and burn injuries. This announcement reinforces Integra's commitment to evidence-based wound reconstruction and has led to a mild positive market reaction for its stock (IART).
List of 16 Acquisitions by Integra LifeSciences (Apr 2026)
This article details Integra LifeSciences' acquisition history, highlighting 16 completed acquisitions. The company's acquisition strategy has focused primarily on the United States, with a concentration in Orthopedics, Regenerative Medicine, and Wound Care sectors. The most recent acquisition was Acclarent in December 2023 for $275M.
Vanguard disaggregates holdings; reports zero ownership in Integra (IART)
Vanguard has filed an amended Schedule 13G/A, reporting 0% ownership in Integra LifeSciences Holdings Corp (IART) following an internal realignment on January 12, 2026. This administrative change means Vanguard's subsidiaries will now report beneficial ownership separately, as per SEC Release No. 34-39538, and does not indicate a sale of shares but rather a change in reporting methodology. Investors seeking a full ownership picture should look for subsequent disaggregated filings from Vanguard's entities.
IART SEC Filings - Integra Lifesciences Hldgs Cp 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Integra LifeSciences Holdings Corporation's (IART) SEC filings, including 10-K, 10-Q, and 8-K forms, offering critical regulatory disclosures for investors. It features AI-powered summaries to help users understand complex financial reports, executive compensation structures, and governance matters. Recent filings detail financial results, goodwill impairment, insider trading activities, and changes to executive severance plans.
Integra LifeSciences (NASDAQ:IART) Beats Q4 2025 Earnings Estimates, Provides 2026 Outlook
Integra LifeSciences (NASDAQ:IART) announced its Q4 2025 financial results, surpassing earnings estimates but falling slightly short on revenue. The company reported adjusted EPS of $0.83 against an estimate of $0.8163, with revenue at $434.93 million, just under the $438.21 million consensus. Following the announcement, the stock showed a cautiously positive market reaction, trading higher in pre-market sessions, and the company also provided its financial guidance for the full year 2026.
Integra (IART) CFO granted 111,179 RSUs; 8,089 shares withheld for tax
Integra LifeSciences Holdings Corp (IART) CFO Lea Daniels Knight was granted 111,179 restricted stock units (RSUs) which will vest over a three-year period. Concurrently, 8,089 shares were disposed of at $9.61 per share to cover tax obligations related to this equity grant. Following these transactions, Ms. Knight directly holds 50,489 common shares of Integra LifeSciences.
Integra (IART) EVP receives 92,108 RSUs and surrenders shares for taxes
Michael J. McBreen, EVP & President, CSS at Integra LifeSciences Holdings Corp (IART), was granted 92,108 restricted stock units (RSUs) with a three-year vesting schedule. To cover tax obligations, McBreen disposed of 2,354 and 7,247 common shares in tax-withholding transactions, not open-market sales. Following these transactions, he directly holds 60,743 common shares and the newly granted 92,108 RSUs.
Integra (IART) CEO granted 343,393 restricted stock units as deferred pay
Integra LifeSciences Holdings Corp. President & CEO Poul Mojdeh was granted 343,393 restricted stock units (RSUs) as deferred compensation. These RSUs will vest in three equal annual installments starting March 11, 2026, and will be delivered as common stock after her separation from service. This grant brings her total reported RSU holdings to 445,691 units.
Integra (NASDAQ: IART) EVP gets 43,350 RSUs, shares withheld for tax
Integra LifeSciences EVP Robert T. Davis Jr. received a grant of 43,350 restricted stock units (RSUs) on March 11, 2026, vesting over three years. To cover tax obligations related to this grant, 8,487 shares at $9.61 and 687 shares at $9.55 were withheld, totaling 9,174 shares. After these transactions, Davis directly holds 66,387 common shares and 43,350 RSUs, which are not open-market sales but tax-withholding transactions.
Integra Lifesciences (IART) EVP reports major RSU grant and vesting
Integra Lifesciences' EVP and President, International, Harvinder Singh, received a grant of 60,865 restricted stock units (RSUs) on March 11, 2026, which will vest over three years. Additionally, earlier RSU awards vested, leading to the conversion of 20,138 units into common stock, and 6,652 shares were withheld for tax obligations. After these transactions, Singh directly holds 21,690 shares of common stock, reflecting routine compensation activities rather than open-market trades.
Integra Lifesciences (IART) EVP gets 41,783 RSUs, 5,420 shares for tax
Integra Lifesciences' EVP & CHRO, Chantal Veillon-Berteloot, received 41,783 restricted stock units (RSUs) with a three-year vesting schedule. Simultaneously, 5,420 shares were disposed of at $9.61 per share to cover tax liabilities, a common practice for equity compensation. Following these transactions, Veillon-Berteloot directly owns 22,227 shares of common stock in the company.
Integra LifeSciences Holdings (IART) Quarterly Losses Challenge Bullish Margin Recovery Narrative
Integra LifeSciences Holdings (IART) reported a basic EPS loss of US$0.02 for Q4 FY 2025 and an annual loss of US$6.74, along with a significant net loss of US$516.5 million over the past year. Despite analyst predictions of revenue growth and a shift to profitability, the company's current financial performance, including a large trailing net loss and high net debt, challenges this bullish margin recovery narrative. Investors are weighing the potential for future growth against ongoing profitability issues and weak interest coverage.
Citigroup Maintains Sell Rating on IART and Lowers Price Target
Citigroup has maintained its "Sell" rating on Integra Lifesciences (IART) and lowered its price target from $11.00 to $9.00, an 18.18% decrease. This decision reflects a cautious outlook from Citigroup, aligning with a recent trend of declining price targets from other analysts. Despite this, the average one-year price target from 7 analysts suggests a potential upside of 63.86%, while GuruFocus estimates a significant upside of 186.13% based on its GF Value.
Integra LifeSciences, GE HealthCare, Bausch + Lomb, ICU Medical, and Universal Health Services Shares Are Falling, What You Need To Know
Shares of Integra LifeSciences, GE HealthCare, Bausch + Lomb, ICU Medical, and Universal Health Services dropped following a disappointing February jobs report that showed an unexpected contraction in employment, particularly in the healthcare sector. The report indicated a loss of 92,000 nonfarm payroll jobs and 28,000 positions in healthcare, raising concerns among investors about a potential economic slowdown and reduced demand for healthcare services. ICU Medical, in particular, saw a 3.9% decline, adding to its year-to-date losses, despite having a volatile stock performance over the past year.
Earnings call transcript: Integra LifeSciences beats Q4 2025 EPS forecast
Integra LifeSciences (IART) reported strong Q4 2025 earnings, surpassing EPS and revenue forecasts with adjusted EPS of $0.83 and revenue of $435 million. The company's stock rose 2.24% in premarket trading following the announcement, reflecting investor confidence despite challenging market conditions throughout the year. Integra provided 2026 guidance, expecting revenue between $1.66 billion and $1.7 billion, and adjusted EPS of $2.30 to $2.40.
Integra LifeSciences Opens Weak with 8.37% Gap Down Amid Market Concerns
Integra LifeSciences Holdings Corp. experienced a significant 8.37% gap down at market open, contributing to a 2.24% daily decline and a 1.82% monthly downturn, contrasting with the S&P 500's performance. The company, a small-cap player in the Pharmaceuticals & Biotechnology sector, has a market capitalization of USD 1,011 million, a P/E ratio of 9.00, and a debt-to-equity ratio of 1.52, with no dividend yield. Technical indicators, including moving averages, MACD, KST, and Bollinger Bands, reflect a bearish sentiment for the stock.
Integra LifeSciences Holdings Corp. Sees Revision in Stock Evaluation Amid Market Dynamics
Integra LifeSciences Holdings Corp. has experienced significant stock performance declines over the past year and three years, despite a modest monthly gain. The company's year-to-date results are unfavorable compared to the S&P 500, and technical indicators suggest a bearish sentiment. Investors will closely monitor its performance amidst these market challenges.
Integra LifeSciences Holdings Corporation (NASDAQ:IART) Given Consensus Recommendation of "Reduce" by Analysts
Integra LifeSciences Holdings Corporation (NASDAQ:IART) has received a consensus "Reduce" recommendation from seven research firms, with an average 12-month price target of $14.80. This comes despite the company slightly beating Q4 earnings and revenue estimates, as it still maintains a negative net margin and its FY2026 guidance is below analyst expectations. Institutional investors have actively traded the stock, with several hedge funds increasing their holdings.
Integra LifeSciences Holdings Corporation (NASDAQ:IART) Q4 2025 Earnings Call Transcript
Integra LifeSciences reported Q4 2025 earnings, exceeding EPS expectations at $0.83 against a $0.79 forecast. The company outlined its strategic imperatives for 2026, focusing on strengthening quality, supply chain reliability, accelerating growth, and igniting innovation, while navigating tariff uncertainties and continuing remediation efforts for certain products like MediHoney. Despite some operational challenges and supply constraints impacting organic growth, the underlying demand for its products remains strong, with key products like SurgiMend expected to relaunch in Q4 2026.
